J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

Patient Medical Information

How Does DARZALEX FASPRO Work?

Last Updated: 01/09/2025

summary

Here is a passage from the DARZALEX FASPRO PRESCRIBING INFORMATION which may be helpful in addressing your question:

How Does DARZALEX FASPRO Work?

  • DARZALEX FASPRO is a prescription medicine used alone or in combination with other anti-cancer medicines to treat adult patients with multiple myeloma or newly diagnosed light chain (AL) amyloidosis.1
  • DARZALEX FASPRO is made up of 2 active ingredients1:
    • Daratumumab: the main active ingredient. For information on how daratumumab works, see Figure: How Daratumumab Works.
    • Hyaluronidase: helps daratumumab to be absorbed into the body when injected under the skin.

How Daratumumab Works1

Abbreviation: CD38, cluster of differentiation 38.

additional information

This information is provided ONLY in response to your request and is not intended as medical advice, to promote the use of our product, or suggest using it in any manner other than as described in the PRESCRIBING INFORMATION. All decisions regarding your medical treatment should be made with your healthcare professional(s). Please contact your healthcare professional(s) to discuss the information in this response.

Please refer to the attached full PRESCRIBING INFORMATION and the PATIENT INFORMATION for DARZALEX FASPRO.1

 

References

1 DARZALEX FASPRO (daratumumab and hyaluronidase) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf